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and c Department of Reproductive Endocrinology and Infertility, Stanford University, Palo Alto, CaliforniaObjective: To report live birth rates (LBR) and total aneuploidy rates in a series of patients with balanced translocations who pursued
in vitro fertilization (IVF)–preimplantation genetic diagnosis (PGD) cycles.
Design: Retrospective cohort analysis.
Setting: Genetic testing reference laboratory.
Patient(s): Seventy-four couples who underwent IVF-PGD due to a parental translocation.
Intervention(s): IVF cycles and embryo biopsies were performed by referring clinics. Biopsy samples were sent to a single reference lab
for PGD for the translocation plus 24-chromosome aneuploidy screening with the use of a single-nucleotide polymorphism (SNP)
microarray.
Main Outcome Measure(s): LBR per biopsy cycle, aneuploidy rate, embryo transfer (ET) rate, miscarriage rate.
Result(s): The LBR per IVF biopsy cycle was 38%. LBR for patients reaching ET was 52%. Clinical miscarriage rate was 10%. Despite a
mean age of 33.8 years and mean of 7 embryos biopsied, there was a 30% chance for no chromosomally normal embryos. Maternal age
>35 years, day 3 biopsy, and having fewer than ﬁve embryos available for biopsy increased the risk of no ET.
Conclusion(s): IVF-PGD for translocation and aneuploidy screening had good clinical outcomes. Patients carrying a balanced trans-Use your smartphonelocation who are considering IVF-PGD should be aware of the high risk of no ET, particularly in
women R35 years old. (Fertil Steril 2015;103:1037–42. 2015 by American Society for
Reproductive Medicine.)
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Whereas expectant management has
the lowest treatment-related costs,
there is a higher risk of miscarriage,
reaching 50% for most translocations
(1, 2). Gamete or embryo donation can
eliminate the risk associated with the
translocation, but has higher costs of
treatment and does not maintain a1037
ORIGINAL ARTICLE: GENETICSgenetic link to both parents, which is extremely important to
some couples. IVF-PGD is a treatment option often used for
individuals with balanced translocations in an effort to
improve the likelihood of achieving a healthy pregnancy (3,
4) while maintaining a genetic link to both parents. While
initial studies of translocation carriers who pursued IVF-
PGD using ﬂuorescence in situ hybridization (FISH) have
shown reduction in miscarriage rates compared to the
expectant management population (5-12), reported live
birth rates per cycle ranged from 12.7-22% (7,12-14). It
should be noted that these early studies largely consisted of
day 3 biopsies.
The accuracy and scope of PGD has improved with the
ability to perform concurrent 24-chromosome aneuploidy
screening in addition to testing for the speciﬁc unbalanced
chromosome products expected to result from the parental
translocation (15–18). The addition of 24-chromosome
screening with PGD for translocations often decreases the
number of embryos with ‘‘normal’’ (euploid) results to trans-
fer, but has the potential to increase the implantation rate
per normal embryo transferred and to reduce the risk of
miscarriage due to chromosomal defects missed with targeted
or limited testing.
The aim of the present study was to assess live birth out-
comes in a cohort of patients with balanced translocations
who pursued IVF with PGD using 24-chromosome SNP mi-
croarray analysis and a bioinformatics technique.MATERIALS AND METHODS
This was a retrospective cohort study of 74 completed IVF-
biopsy cycles. All PGD cases received from January 2010 to
August 2012 for the indication of a parental translocation,
as conﬁrmed by standard karyotype analysis, were included
in the study. All samples were analyzed at a single reference
laboratory. Before embryo samples were accepted for testing,
each parent's karyotype report was reviewed to determine
whether there was adequate single-nucleotide polymorphism
(SNP) coverage on the microarray to detect the potential com-
binations of unbalanced chromosome products that could
result from the parent's balanced translocation. IVF cycles
were performed by referring clinics. After fertilization, em-
bryos underwent a single-cell biopsy on day 3, or a trophec-
toderm biopsy on day 5/6, according to each clinic's standard
procedures. Embryo biopsies were shipped on dry ice, and
parental blood or buccal samples were shipped at room tem-
perature to the reference laboratory for analysis.
PGD for the parental translocation with concurrent
24-chromosome aneuploidy screening was performed with
the use of Illumina Cyto12 SNP microarrays and Parental
Support (19). This methodology incorporates parental SNP
genotype information to predict the possible SNP genotypes
for an embryo. For each chromosome, the algorithm compares
the observed SNP data with each of the predicted allele distri-
butions for each copy number hypothesis and identiﬁes that
with the maximum likelihood. Inclusion of parental geno-
typic information allows for identiﬁcation of both chromo-
some content and parental source of chromosomes for each
embryo biopsy sample. Thus, if there was a chromosome ab-1038normality in an embryo sample that involved the chromo-
some of interest (given the translocation) but was of the
wrong parent of origin (did not match with the parent who
was the translocation carrier), we were able to determine
that the chromosome error was sporadic and not related to
the parental translocation. Therefore, inclusion of the
parental genotypic information allowed for us to calculate
the unbalanced chromosome rates in the embryo samples.
This analysis did not allow us to differentiate euploid versus
balanced. Accordingly, the embryo results were classiﬁed as
‘‘unbalanced’’ if the abnormal chromosome was involved in
the parental translocation, ‘‘euploid’’ if normal and/or
balanced without other aneuploidy, or ‘‘sporadic aneuploid’’
if other chromosomes were abnormal. Embryos affected by
unbalanced structural rearrangements in addition to sporadic
aneuploidy were classiﬁed as ‘‘combined abnormalities.’’ To-
tal abnormality rate was calculated as the sum of unbalanced
translocation rates, sporadic aneuploidy rates, and combined
abnormality rates.
Cycle outcomes were requested from clinics with the use
of a deﬁned data collection protocol for patients with at least
one euploid embryo available for transfer. Outcomes obtained
included number of euploid embryos transferred, chemical
pregnancy according to positive hCG, clinical pregnancy ac-
cording to fetal heart beat (FHB), and live birth (LB) data. Cy-
cles were examined by type of translocation (reciprocal vs.
Robertsonian), parent of origin, day of biopsy, and maternal
age (<35 or R35 years). If multiple embryo transfers (ETs)
were performed from a single biopsy cycle, outcomes were
combined for the calculations per cycle but not for the calcu-
lations that were reported per ET. Clinical pregnancy loss was
deﬁned as the presence of a FHBwith no subsequent LB. Over-
all miscarriage rate was deﬁned as a positive chemical preg-
nancy with no resultant LB. Successful pregnancies were
deﬁned by a LB.
Statistical analyses were performed using a combination
of the Welch t test, F test for variance, and chi-square test as
indicated. The cycle data provided by the reference laboratory
was deidentiﬁed for research purposes. As such, this study
was determined to be exempt from Institutional Review Board
review.RESULTS
Of the 74 completed IVF-biopsy cycles in couples with
balanced translocations, 52 (70.3%) resulted in one or more
euploid embryos. We calculated the euploid versus aneuploid
(unbalanced, sporadic, combined) rates based on the number
of embryo samples with results. The number of embryo sam-
ples with no results on day 5 testing was 7 out of 109 (6%),
and on day 3 testing was 29 out of 466 (6%). Two of the 52
cycles had two ETs, resulting in a total of 54 ETs. There
were a total of 82 embryos transferred in this patient cohort,
and the overall implantation rate was 49% (40/82).
Total chromosome abnormality rates for embryos were
analyzed separately and are presented in Table 1. Rates for
both unbalanced translocation and combined abnormality
(unbalanced translocation with sporadic aneuploidy) were
signiﬁcantly higher for reciprocal translocation carriersVOL. 103 NO. 4 / APRIL 2015
TABLE 1
Embryo results.
Population
No. of
embryos
Unbalanced
translocation
rate, %
Sporadic
aneuploidy
rate, %
Combined
abnormality
rate, %a
Total
abnormality
rate, %b
Euploid
rate, %
Total 539 18 36 20 74 26
Robertsonian translocation 201 6e 55e 2e 63e 37e
Reciprocal translocation 338 24e 26e 31e 81e 19e
Maternalc 247 24e 27e 23 74 26
Paternald 292 12e 45e 18 75 25
Day 3 Biopsy 437 17 39e 22 78e 22e
Day 5 Biopsy 102 22 24e 12 58e 42e
Maternal ageR35 y 202 16 34 31e 81e 19e
Maternal age <35 y 337 19 38 14e 71e 29e
a Unbalanced translocations with sporadic aneuploidy.
b Sporadic aneuploidy, unbalanced translocations, and unbalanced translocations with sporadic aneuploidy.
c Maternal carriers of translocations.
d Paternal carriers of translocations.
e Signiﬁcant differences (P< .05) within categories (Welch t test with F test for variance performed as appropriate).
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There was a statistically signiﬁcant difference in the rate of
embryos with unbalanced translocations between male and
female translocation carriers (12% vs. 24%; P< .05). However,
there was no statistically signiﬁcant difference in the total
aneuploidy rates between male and female translocation car-
riers. There was also a statistically signiﬁcant difference in the
rate of sporadic aneuploidy between day 3 and day 5 biopsy
samples (P< .05). This translated into a signiﬁcantly higher
rate of total aneuploidy in the day 3 biopsy group. Similarly,
women in theR35 years age cohort had a greater total aneu-
ploidy rate compared with their younger counterparts.
Likelihood of reaching ET and pregnancy outcomes per
ET are presented in Table 2. The average maternal age in this
cohort was 33.8 years, and the average number of embryos bio-
psied per cycle was 7.2. Despite this, 30% of cycles had no
euploid embryos. The day 5 biopsy group and maternal age
<35 years group had higher rates of euploid embryos, support-
ing the higher subsequent rates of ET comparedwith their coun-
terparts. However, it should be noted that there were no
differences in implantation rates within either of these groups
once ETwas reached. Regarding the reciprocal versusRobertso-
nian translocation carriers, there was no signiﬁcant difference
in reaching ET despite having a signiﬁcant difference in the
number of available euploid embryos. There was no signiﬁcant
difference between the demographic groups regarding LB rates
once ET was achieved, and overall LB rate per embryo transfer
was 52%. Analysis of the number of embryos available for bi-
opsywas performed, andhavingﬁveormore embryos available
for biopsy was associatedwith a signiﬁcantly greater chance of
reaching ET across all cohorts (P¼ .0009).
Pregnancy outcomes per biopsy cycle are presented in
Table 3. Overall, IVF-PGD for 24 chromosomes in carriers of
balanced translocations yielded a 38% LB rate per biopsy cy-
cle. Women <35 years old had higher LB rates per biopsy cy-
cle than women R35 years old (49% vs. 23%; P¼ .02).
However, there was no signiﬁcant difference in LB rates be-
tween the maternal age groups once ET was reached (P¼ .1;
Table 2). Other than maternal age, there were no signiﬁcantVOL. 103 NO. 4 / APRIL 2015differences between demographic groups regarding LB rates
per biopsy cycle.
Pregnancy loss is important to both clinicians and pa-
tients. To address differences in perspective between them,
our study calculated clinical pregnancy loss (loss after FHB/
clinical pregnancy) independently from total pregnancy loss
(any pregnancy loss after hCG/biochemical pregnancy). Preg-
nancy loss was calculated per pregnancy. Of the 54 ETs in this
study, 34 resulted in biochemical pregnancy, 31 resulted
in clinical pregnancy, and 28 pregnancies resulted in
LB (Table 3). Thus, the clinical pregnancy loss rate was 10%
(3/31) and the total pregnancy loss rate was 18% (6/34).
It should be noted aswell that not all available euploid em-
bryoswere transferred. Of the 52 cases resulting in euploid em-
bryos available for transfer, two pursued a second transfer at
the time data was collected. However, within this group of
52 cases, 26 had remaining euploid embryos of unknown em-
bryo quality thatmay have been frozen for future ET attempts.DISCUSSION
Patients who carry balanced translocations are faced with
multiple treatment options but little outcome data with which
to guide their decisions. Although earlier studies examining
IVF-PGD in this population reported clinical pregnancy rates
per ET (15, 20, 21), they did not routinely evaluate LB rate per
cycle. The limitation of this approach is underscored by the
fact that 30% of our cohort did not reach ET, owing to all
embryos being identiﬁed as abnormal via PGD.
Simultaneous translocation and aneuploidy screening has
been previously achieved by others. However, those studies
featured either small series of patients (15, 18, 22) or
deﬁned successful outcomes as both LB and ongoing
pregnancy (17). The present study included 74 couples who
pursued IVF-PGD plus 24-chromosome screening because
of a parental translocation. We evaluated LB rate per biopsy
cycle in these translocation carriers and secondarily assessed
the total aneuploidy rates in the tested embryo samples. In this
study we report a 38% LB rate per biopsy cycle and a 52% LB1039
TABLE 2
Likelihood of reaching embryo transfer (ET) and outcomes per ET.
Population
Average
maternal age (y)
Mean no. of
embryos biopsied, %
Cycles
with no ET, %
Cycles
with ET, %
FHB per
ET, %
LB per
ET, %
Total 33.8 7.2  4.0 30 70 57 52
Robertsonian translocation 33.9 6.2  3.9 19 81 56 52
Reciprocal translocation 34.0 8  4.3 38 62 59 52
Maternala 34.5 6.4  3.9 31 69 67 59
Paternalb 33.5 8.1  4.4 23 77 48 44
Day 3 biopsy 34.1 8.1  4.2 38c 62c 62 56
Day 5 biopsy 33.7 5  3.4 5c 95c 50 45
Maternal ageR35 y 38.0 6.5  3.9 45c 55c 50 39
Maternal age <35 y 30.8 7.7  4.3 19c 81c 61 58
Note: FHB ¼ fetal heart beat; LB ¼ live birth.
a Maternal carriers of translocations.
b Paternal carriers of translocations.
c Signiﬁcant differences (P< .05) within categories (Welch t test with F test for variance performed as appropriate).
Idowu. 24-chromosome PGD for translocations. Fertil Steril 2015.
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parental carrier of a balanced translocation.
The use of SNP microarrays allowed for testing of each
embryo biopsy sample for the parental translocation in addi-
tion to simultaneous 24-chromosome aneuploidy screening.
This allowed for calculation of the total aneuploidy rate
(unbalanced translocation plus sporadic aneuploidy) in the
biopsied embryos. This ﬁgure is most clinically relevant for
patients, because the goal of IVF-PGD is to identify a chromo-
somally normal embryo and abnormalities of any chromo-
some can result in failed implantation, miscarriage, or the
birth of a child with congenital anomalies. In our cohort of
PGD cycles, 38% of embryos biopsied were affected by an un-
balanced translocation and 36% by sporadic aneuploidy. This
led to a total aneuploidy rate of 74%. Our overall rates of
chromosomal abnormality (Table 1) were similar to previous
studies featuring simultaneous translocation and aneuploidy
screening (18, 22). The rate of sporadic and combined
abnormalities between reciprocal and Robertsonian groups
was identical (57%), which is reﬂective of the similar ages
of these groups in the present study. Further review of the
abnormality rates between our demographic groups showed
that reciprocal translocation carriers had a signiﬁcantly
higher rate of unbalanced embryos than Robertsonian
translocation carriers, consistent with earlier studies (4, 5).
There was a statistically signiﬁcant difference in the rate
of unbalanced embryos between male and female
translocation carriers; however, there was no statistically
signiﬁcant difference in the total aneuploidy rates between
those two groups. The rates of unbalanced translocations
were similar between day 3 and day 5 biopsy groups, and
between maternal age groups. Further analysis showed
signiﬁcantly higher total aneuploidy rates in the day 3
biopsy and maternal age R35 years groups. Because of the
high total aneuploidy rate in our cohort of PGD cycles, 30%
(22 out of 74 cycles) of the patients did not reach ET.
Inclusion of parental genotypic information provided
additional diagnostic beneﬁt. For both Robertsonian and
reciprocal translocations, if there was a chromosome abnor-
mality in an embryo sample that involved the chromosome1040of interest (given the translocation) but was of the wrong
parent of origin (did not match to the parent who was the
translocation carrier) we were able to determine that the chro-
mosome error was sporadic and therefore unrelated to the
parental translocation. This prevented erroneous documenta-
tion of sporadic aneuploidies as inherited unbalanced translo-
cations. For the Robertsonian translocation group, there were
a total of 201 embryo samples tested (Table 1). Of these, 127
embryo samples were aneuploid, consisting of 110 embryo
samples with sporadic aneuploidy, 12 embryo samples with
inherited (unbalanced) aneuploidy, and 5 embryo samples
with both sporadic and inherited (combined) aneuploidy.
For the reciprocal translocation group there were a total of
338 embryo samples tested (Table 1). Of these, 274 embryo
samples were aneuploid, consisting of 87 embryos with spo-
radic aneuploidy, 83 embryo samples with inherited (unbal-
anced) aneuploidy, and 104 embryo samples with both
sporadic and inherited (combined) aneuploidy. The rate of in-
herited (unbalanced) aneuploidy for Robertsonian transloca-
tions in this study was noticeably lower (6%) than rates
(11.5%–12%) seen in earlier similar studies using comparative
genomic hybridization (CGH) for chromosome aneuploidy
screening (15, 17). This is likely due, in part, to the
limitation of CGH to detect the parental origin of
aneuploidy, resulting in the inability to determine whether
or not a chromosome aneuploidy matched the correct
parental homologue to be related to the parental
translocation. In the present study, incorporation of
parental SNP genotype information allowed for the
exclusion of embryo samples from the unbalanced
translocation category if the chromosome aneuploidy
involved a chromosome related to the translocation but was
of the wrong parental homologue and thus was unrelated to
the parental translocation. Such embryo results were
categorized as ‘‘sporadic aneuploidy’’ rather than
‘‘unbalanced translocations.’’ Had this exclusion criterion
not been included, Robertsonian unbalanced translocation
rates would have been closer to what has been reported in
previous similar studies using CGH (15, 17). The reciprocal
unbalanced translocation rates would have also been higherVOL. 103 NO. 4 / APRIL 2015
TABLE 3
Outcomes per biopsy cycle.
Population No. of cycles No. of ETs
No. of biochemical
pregnancies
No. of clinical
pregnancies
No. of
cycles with LB
LB rate per
biopsy cycle
Total 74 54 34 31 28 38%
Robertsonian translocation 32 27 16 15 14 44%
Reciprocal translocation 42 27 18 16 14 33%
Maternala 39 27 19 18 16 41%
Paternalb 35 27 15 13 12 34%
Day 3 biopsy 54 34 22 21 19 35%
Day 5 biopsy 20 20 12 10 9 45%
Maternal ageR35 y 31 18 9 9 7 23%c
Maternal age <35 y 43 36 25 22 21 49%c
a Maternal carriers of translocations.
b Paternal carriers of translocations.
c Signiﬁcant differences (P< .05) within categories (Welch t test with F test for variance performed as appropriate).
Idowu. 24-chromosome PGD for translocations. Fertil Steril 2015.
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should be noted that our patient cohort likely presented for
IVF owing to reproductive difﬁculty, recurrent pregnancy
loss, or previous child with a chromosome abnormality;
therefore, the data may be biased toward unbalanced
chromosome products compared with all translocation
carriers.
Prognostic indicators for ET are likely to at least partially
drive patient decision-making processes, and are therefore
important to report. In the present study, factors such as
maternal age, day of biopsy, and number of embryos avail-
able for biopsy affected couples' chances of reaching ET. Spe-
ciﬁcally, women aged R35 years had higher rates of no
euploid embryos available for transfer compared with women
aged <35 years (45% vs. 19%; P¼ .02). This occurred despite
these groups having similar rates of embryos affected by un-
balanced translocations, indicating that the difference is not
in the rate of unbalanced translocations but rather in the
rate of sporadic aneuploidy. Indeed, this rate was higher in
the maternal age group ofR35 years when the combined ab-
normality rate (unbalanced translocation with sporadic aneu-
ploidy) was considered. Likewise, patients who pursued day 3
biopsies had lower odds of reaching ET than patients who pur-
sued day 5 biopsies (62% vs. 95%; P¼ .005), despite similar
rates of embryos affected by unbalanced translocations.
Again, this would suggest that the difference is not in the
rate of unbalanced translocations but rather in the rate of spo-
radic aneuploidy. This is important because aneuploidies
generally decrease from day 3 to day 5, suggesting that
most unbalanced embryos are compatible with development
from day 3 to day 5. There was also a signiﬁcantly lower
rate of sporadic aneuploidies in patients with day 5 embryo
biopsies. This is likely a reﬂection of improved embryo selec-
tion and/or reduced mosaicism at the blastocyst stage.
Because this was a retrospective cohort frommultiple centers,
we were unable to determine if this was due to differences in
patient selection for undergoing day 5 biopsies or to the
increased accuracy of testing. However, implantation rates
in day 3 versus day 5 biopsies were the same once ET was
reached. Furthermore, there was no signiﬁcant difference in
LB rates between these groups once ET was reached, indi-VOL. 103 NO. 4 / APRIL 2015cating that the impact of the biopsy technique does not extend
beyond the ET phase of a given cycle.
The availability of ﬁve or more embryos for biopsy was
associated with a signiﬁcantly greater chance of reaching
ET. This suggests that translocation carriers undergoing IVF
with PGD who are predicted to yield fewer than ﬁve embryos
in a given cycle should consider banking embryos from two or
more cycles. This may increase the chance of reaching ET and
live birth, thus obviating the need for alternate reproductive
options such as gamete donation.
The success rate (LB rate per biopsy cycle) of PGD with
translocation plus 24-chromosome screening in the present
study was 38%, which is higher than what has been reported
in earlier studies (12.7%–22%) which tested for a limited
number of chromosomes via FISH (7, 12–14). Earlier studies
have reported clinical miscarriage rates ranging from 7% (5)
to 33% (6). The clinical miscarriage rate in the present study
was 10% (3/31), which was within the range of reported
clinical miscarriage rates in studies using CGH (15, 17). The
overall pregnancy loss rate (including all positive chemical
pregnancies with no resultant LB) was 18% (6/34). In
general, LB rate per biopsy cycle with IVF-PGD (38%) in the
present study was lower than what has been reported
with expectant management (43%–60%) for most patients
(21, 23–25). In this context, expectant management with no
PGD certainly remains an option for translocation carriers.
Owing to our study design, we were unable to determine if
some of the patients also had a history of infertility or
recurrent pregnancy loss, which could lead to a lower LB
rate in our study population compared with historical
control subjects. Overall, reduced miscarriage rate per
pregnancy, lower risk of an ongoing pregnancy with an
unbalanced chromosome rearrangement, and the option to
try again with IVF-PGDmay make IVF-PGD an attractive op-
tion for some patients.CONCLUSION
This is a report of IVF cycles with PGD for translocations in
addition to 24-chromosome screening. The ﬁndings indicate
that IVF-PGD with translocation plus aneuploidy screening1041
ORIGINAL ARTICLE: GENETICSis a more reliable approach to lowering miscarriage rates in
patients with a balanced translocation than PGD methods
that do not use 24-chromosome screening. Our study popula-
tion did consist of considerably more day 3 biopsy cycles
(n ¼ 54) than day 5 biopsy cycles (n ¼ 20). Additionally,
referral indications beyond parental translocation and
maternal age were not assessed. As a result, differences in
the sporadic aneuploidy rate between day 3 and day 5 em-
bryos may be a reﬂection of patient age, self-selection of
normal embryos to the blastocyst stage, and/or patient char-
acteristics. Furthermore, embryo samples sent to the reference
laboratory for testing were presumed to come from the same
IVF biopsy cycle. It is possible, however, that referral centers
held (batched) embryo samples from different IVF cycles and
then sent them in for PGD testing. Because this was a retro-
spective analysis, a limitation of the study is that this was
not conﬁrmed. However, this practice is thought to be un-
likely, considering concerns over potential sample degrada-
tion at individual centers not equipped for sample storage.
Until larger prospective studies of IVF-PGD are performed,
the ﬁndings of the present study can be used in counseling
patients considering the use of PGD for a balanced transloca-
tion about expected success rates seen with this reproductive
treatment option.REFERENCES
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